Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing resveratrol-based products for neuroinflammation-related conditions. Its pipeline includes JNS101, in Phase II for Friedreich's ataxia; JNS108, in Phase II for mild cognitive impairment and early Alzheimer's disease; JNS102, in Phase II for mucopolysaccharidosis type 1; JNS107, in Phase II for mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome; and JNS115, in Phase IIa for Parkinson's disease. The company has also entered strategic collaborations with Zina Biopharmaceuticals, LLC for a Phase 2a Parkinson's disease study of Resveratrol (JOTROLTM) and with Aquanova AG on consumer nutritional products aimed at longevity, aging, and healthspan. Founded in 2016 and formerly known as Jupiter Orphan Therapeutics, Inc., the company is headquartered in Jupiter, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JUNS
|
$0.18
|
-3.1% Downside
|
Fair
|
$30 15,689.5% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-0.8x
|
-2.6x
|
177.1x
|
7.165 M
|
9.635 M
|
39.6%
|
62.0%
|
-21.2
|
—
|
63.0%
|
